Following this reasoning makes wonder if mebendazole could be another option for get rid off senescent cells.
The combination with c60 and PQQ apparently worked very well for the dog:
Does anyone else know if Mebendazole share some other mechanism of action with Dasatinib? or if this conjeture has some more support?
Thx for reminding me about mebendazole Bierak.
Here is a quote of my post in the 'Dog with bowel cancer' thread: (it lived well for another 1.5 years and died at age 14, after being given 2 weeks to live)
I agree that mebendazole works on worms by destabilising microtubules, but there is evidence that it has a similar effect on cancer cells and is effective despite your doubts about bioavailability:
The Anthelmintic Drug Mebendazole Induces Mitotic Arrest and Apoptosis by Depolymerizing Tubulin in Non-Small Cell Lung Cancer Cells:
http://www.ncbi.nlm....ng Cancer Cells
Mebendazole Elicits a Potent Antitumor Effect on Human Cancer Cell Lines Both in Vitro and in Vivo:
http://www.ncbi.nlm....tro and in Vivo
Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells:
http://www.ncbi.nlm.... Melanoma Cells
Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice:
http://www.ncbi.nlm....ed in nude mice
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme:
http://www.ncbi.nlm....toma multiforme
...As well as destabilising microtubules Mebendazole has also been shown to boost OXPHOS expression while suppressing ROS levels, as has deoxysappanone B, found in Green Tea and most other microtubule destabilizers...
http://www.longecity...ndpost&p=593124
So Mebendazole is worth a look as a cheap and easily available (here) alternative or adjunct to Dasatinib. (Its not available in the USA and UK anymore. Probably because of the above effects.)
The question is:
How strong is it? ie: What dose is required to be the equivalent of 300 mg of D?
The full text of:
Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
http://mcr.aacrjourn...t/6/8/1308.long
...Figure 2A shows that 24 h after cells were treated with 1 μmol/L mebendazole, 25% of M-14 cells and 31% of SK-Mel-19 were positive for Annexin V staining, indicating that these cells were undergoing apoptosis...
...We identified Bcl-2 as a critical mediator of the differential cellular response to mebendazole treatment in melanocytes versus melanoma cells. After mebendazole treatment, Bcl-2 is rapidly phosphorylated in melanoma cells but not in melanocytes. In the literature, the functional significance of Bcl-2 phosphorylation remains controversial. Some reports suggest that Bcl-2 phosphorylation renders the protein inactive and cells more sensitive to induction of apoptosis (15), whereas other studies suggest that the antiapoptotic function of Bcl-2 is enhanced by phosphorylation (40). The differing consequences of Bcl-2 phosphorylation may be attributed to the agent used to induce phosphorylation in these studies. When antimitotic agents are used to induce Bcl-2 phosphorylation, this typically results in Bcl-2 inactivation. Consistent with this notion, our data suggest that tubulin-disrupting mebendazole causes Bcl-2 phosphorylation, which prevents its interaction with proapoptotic Bax, thereby promoting selective apoptosis in melanoma cells. Furthermore, we show that reduction of Bcl-2 protein levels through RNA interference sensitized initially mebendazole-resistant melan-a melanocytes to the growth-inhibitory properties of mebendazole. This result further supports the importance of Bcl-2 in the differential cellular responses between melanoma cells and melanocytes to mebendazole-mediated growth inhibition. In contrast, Sasaki et al. (7) reported that Bcl-2 phosphorylation was not a necessary event for mebendazole-induced apoptosis in non–small cell lung carcinoma cells based on the observation that Bcl-2 phosphorylation occurred in response to mebendazole treatment in H460 cells but not in A549 cells. However, it should be noted that A549 cells seem to express little or no Bcl-2 protein, whereas both the melan-a and M-14 cells used in our study express comparable levels of Bcl-2 protein, readily detectable by Western blotting (Fig. 4). In addition, Bcl-2 phosphorylation was observed in other melanoma cell lines (Yusac-2 and SK-Mel-19) treated with mebendazole (data not shown). These differences might explain the discrepancies between our work and the results reported by Sasaki et al...
So it looks like a god adjunct to get rid certain cancerous cells, but not as a replacement for D?
Note that all these compounds seem to be specific to certain cell types, so a cocktail of D, Q, M and Navitoclax probably has additive and possibly synergistic effects?
http://www.longecity...enolytic-drugs/
Also is 1 μmol/L achievable?
Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts.
http://www.ncbi.nlm....les/PMC1386263/
Edited by Logic, 11 February 2016 - 09:57 PM.